Logo_BMS

 

Lab_name_ita

 

Laboratorio di Bioinformatica e

Biologia Sintetica

Percorso

Silvia Maria Lavezzi


Nome Cognome

Silvia Maria Lavezzi

Mail:

Questo indirizzo email è protetto dagli spambots. E' necessario abilitare JavaScript per vederlo.

Phone:

+39-0382-985746

Fax:

+39-0382-525638

Born in Pavia (PV), on December 31st, 1990

Main affiliation

Dipartimento di Ingegneria Industriale e dell'Informazione

Università degli Studi di Pavia

Via Ferrata 5, I-27100 Pavia, Italy

 

 

Current Position

PhD student, University of Pavia, Italy

Academic Degree

2012 Laurea (BS thesis) in Mathematics at the University of Pavia, Italy
Thesis: Modelli Matematici del Sistema Visivo. Score: 103 out of 110.
2014 Laurea Specialistica (MS degree) in Mathematics at the University of Pavia, Italy
Thesis: Nonlinear Mixed Effects Modelling with Application to Drug-Drug Interactions for an Oncology Compound Development. Score: 110 out of 110 cum laude.

 


Research Interests

Model based drug development, nonlinear mixed effects models, antitumor drugs, bayesian inference, mPBPK-TMDD models for monoclonal antibodies.

 

 

 

Publications

 

S.M. Lavezzi, J. de Jong, M. Neyens, P. Cramer, F. Demirkan, G. Fraser, A. Pristupa, N. Bartlett, M.-S. Dilhuydy, J. Loscertales, A. Avigdor, S. Rule, O. Samoilova, A. Goy, S. Ganguly, M. Salman, A. Howes, M. Mahler, G. De Nicolao, I. Poggesi. Modelling of rituximab clearance reduction due to ibrutinib co-administration. PAGE 26 (2017) Abstr 7139

 

S.M. Lavezzi, Y. Cherkas, N. Haddish-Berhane, S. Jagannatha, G. De Nicolao, D. Ouellet, I. Poggesi. A Shiny App for the Probability of Technical Success of a New Molecular Entity in the Preclinical to Clinical Translational Phase. PAGE 26 (2017) Abstr 7160

 

P. Cramer, F. Demirkan, G. Fraser, A. Pristupa, N.L. Bartlett, M.-S. Dilhuydy, J. Loscertales, A. Avigdor, S.A. Rule, O. Samoilova, A. Goy, S. Ganguly, I. Poggesi, S.M. Lavezzi, G. De Nicolao, J. de Jong, M. Neyens, M. Salman, A. Howes, M. Mahler. Ibrutinib increases the systemic exposure of rituximab: pharmacokinetic results from the Helios trial. 14-ICML, Hematological Oncology, 35(S2), 232-233 (2017)

 

P. Cramer, F. Demirkan, G. Fraser, A. Pristupa, N.L. Bartlett, M.-S. Dilhuydy, J. Loscertales, A. Avigdor, S.A. Rule, O. Samoilova, A. Goy, S. Ganguly, I. Poggesi, S.M. Lavezzi, G. De Nicolao, J. de Jong, M. Neyens, M. Salman, A. Howes, M. Mahler. Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial. ASH 58 (Blood 2016) Abstr 4403 

 

S.M. Lavezzi, S. Zamuner, G. De Nicolao, P. Ma, M. Simeoni. Structural and practical identifiability of some mPBPK-TMDD models. PAGE 25 (2016) Abstr 5876

 

E. Borella, L. Carrara, S.M. Lavezzi, I. Massaiu, E. Sauta, E.M. Tosca, F. Vitali, S. Zucca, L. Pasotti, G. De Nicolao, P. Magni. Methods and tools for multiscale modelling in Systens Pharmacology: a review. PAGE 25 (2016) Abstr 5793

 

S.M. Lavezzi, E. Mezzalana, G. De Nicolao. Toxicity assessment via drug-drug interaction modeling for trabectedin in patients with advanced malignancies. PAGE 24 (2015) Abstr 3393

 

E. Borella, L. Carrara, S.M. Lavezzi, E. Mezzalana, L. Pasotti, G. De Nicolao, P. Magni. Evaluation of software tools for Bayesian estimation on population models with count and continuous data. PAGE 24 (2015) Abstr 3452

 

E. Mezzalana, S.M. Lavezzi, S. Zamuner, G. De Nicolao, P. Ma, M. Simeoni. Integrating Target Mediated Drug Disposition (TMDD) into a minimal physiologically based modelling framework: evaluation of different quasi-steady-state approximations. PAGE 24 (2015) Abstr 3598